Peter Hellemans

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Anas Younes, Catherine Thiéblemont, Franck Morschhauser et al. · The Lancet Oncology · 2014 · 250 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +6

Prognostic value of bcl-2 expression in invasive breast cancer

Peter Hellemans, PA van Dam, Joost Weyler et al. · British Journal of Cancer · 1995 · 187 citations · Full text

Breast Oncology, Oncology, Medicine +5

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit et al. · Clinical Cancer Research · 2013 · 118 citations · Full text

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos et al. · Blood · 2019 · 114 citations · Full text

Effect of <scp>CYP</scp>3A perpetrators on ibrutinib exposure in healthy participants

Jan de Jong, Donna Skee, Joe Murphy et al. · Pharmacology Research & Perspectives · 2015 · 98 citations · Full text